Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

Leuk Lymphoma. 2006 Nov;47(11):2380-7. doi: 10.1080/10428190600821989.

Abstract

The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / immunology*
  • Antigens, CD19 / immunology*
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / genetics
  • Burkitt Lymphoma / immunology*
  • Burkitt Lymphoma / pathology
  • Cell Line, Tumor
  • DNA / biosynthesis
  • Humans
  • Immunotoxins / immunology*
  • Male
  • Mice
  • Mice, SCID
  • Survival Rate

Substances

  • Antibodies
  • Antigens, CD19
  • Immunotoxins
  • DNA